Irawan Vincent, Sung Tzu-Cheng, Higuchi Akon, Ikoma Toshiyuki
1Department of Materials Science and Engineering, Tokyo Institute of Technology, 2 Chome-12-1, Meguro-ku, Tokyo, 152-8550 Japan.
2Department of Chemical and Materials Engineering, National Central University, No. 300 Jung Da Rd., Chung-Li, Taoyuan, 320 Taiwan.
Tissue Eng Regen Med. 2018 Jul 25;15(6):673-697. doi: 10.1007/s13770-018-0135-9. eCollection 2018 Dec.
Cartilage tissue engineering (CTE) aims to obtain a structure mimicking native cartilage tissue through the combination of relevant cells, three-dimensional scaffolds, and extraneous signals. Implantation of 'matured' constructs is thus expected to provide solution for treating large injury of articular cartilage. Type I collagen is widely used as scaffolds for CTE products undergoing clinical trial, owing to its ubiquitous biocompatibility and vast clinical approval. However, the long-term performance of pure type I collagen scaffolds would suffer from its limited chondrogenic capacity and inferior mechanical properties. This paper aims to provide insights necessary for advancing type I collagen scaffolds in the CTE applications.
Initially, the interactions of type I/II collagen with CTE-relevant cells [i.e., articular chondrocytes (ACs) and mesenchymal stem cells (MSCs)] are discussed. Next, the physical features and chemical composition of the scaffolds crucial to support chondrogenic activities of AC and MSC are highlighted. Attempts to optimize the collagen scaffolds by blending with natural/synthetic polymers are described. Hybrid strategy in which collagen and structural polymers are combined in non-blending manner is detailed.
Type I collagen is sufficient to support cellular activities of ACs and MSCs; however it shows limited chondrogenic performance than type II collagen. Nonetheless, type I collagen is the clinically feasible option since type II collagen shows arthritogenic potency. Physical features of scaffolds such as internal structure, pore size, stiffness, etc. are shown to be crucial in influencing the differentiation fate and secreting extracellular matrixes from ACs and MSCs. Collagen can be blended with native or synthetic polymer to improve the mechanical and bioactivities of final composites. However, the versatility of blending strategy is limited due to denaturation of type I collagen at harsh processing condition. Hybrid strategy is successful in maximizing bioactivity of collagen scaffolds and mechanical robustness of structural polymer.
Considering the previous improvements of physical and compositional properties of collagen scaffolds and recent manufacturing developments of structural polymer, it is concluded that hybrid strategy is a promising approach to advance further collagen-based scaffolds in CTE.
软骨组织工程(CTE)旨在通过相关细胞、三维支架和外部信号的组合来获得模仿天然软骨组织的结构。因此,植入“成熟”构建体有望为治疗大面积关节软骨损伤提供解决方案。I型胶原蛋白因其普遍的生物相容性和广泛的临床认可,被广泛用作正在进行临床试验的CTE产品的支架。然而,纯I型胶原蛋白支架的长期性能会受到其有限的软骨生成能力和较差的力学性能的影响。本文旨在为推进I型胶原蛋白支架在CTE应用中提供必要的见解。
首先,讨论I/II型胶原蛋白与CTE相关细胞[即关节软骨细胞(ACs)和间充质干细胞(MSCs)]的相互作用。接下来,强调对支持AC和MSC软骨生成活性至关重要的支架的物理特征和化学成分。描述了通过与天然/合成聚合物混合来优化胶原蛋白支架的尝试。详细介绍了胶原蛋白和结构聚合物以非混合方式组合的混合策略。
I型胶原蛋白足以支持ACs和MSCs的细胞活性;然而,与II型胶原蛋白相比,其软骨生成性能有限。尽管如此,I型胶原蛋白是临床上可行的选择,因为II型胶原蛋白具有致关节炎的潜能。支架的物理特征,如内部结构、孔径、硬度等,对影响ACs和MSCs的分化命运以及分泌细胞外基质至关重要。胶原蛋白可以与天然或合成聚合物混合,以改善最终复合材料的力学和生物活性。然而,由于I型胶原蛋白在苛刻的加工条件下会变性,混合策略的通用性受到限制。混合策略成功地使胶原蛋白支架的生物活性最大化和结构聚合物的机械稳健性最大化。
考虑到胶原蛋白支架先前在物理和组成性质方面的改进以及结构聚合物最近的制造发展,可以得出结论,混合策略是在CTE中进一步推进基于胶原蛋白的支架的一种有前途的方法。